cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.28890889
title: Role of oxysterol 4β-hydroxycholesterol and liver X receptor alleles in pre-eclampsia

description: Liver X receptors (LXRs) are expressed in placenta and may be associated with pre-eclampsia (PE). Oxysterols act as agonists for LXRs. We recently proposed a new blood pressure-regulating circuit with oxysterol 4β-hydroxycholesterol (4βHC) acting as a hypotensive factor <i>via</i> LXRs. This study investigated the association between maternal plasma 4βHC, blood pressure (BP) indices, placental expression of LXR target genes, and patient characteristics using data from the Finnish Genetics of Pre-Eclampsia Consortium (FINNPEC) cohort. Plasma samples of 144 women with PE and 38 healthy pregnant controls as well as 44 PE and 40 control placental samples were available. In addition, genetic data from the FinnGen project was utilized to explore the associations of LXR alleles with PE and pregnancy hypertension. There were no significant associations between 4βHC and BP or maternal and perinatal characteristics in FINNPEC cohort. However, plasma 4βHC was inversely correlated with the maternal body mass index. There were no associations with the genetic variants of LXRs with PE in FinnGen. LXR target genes APOD, SCARB1, TGM2, and LPCAT3 were expressed differently between PE and normal pregnancies in placental samples of FINNPEC. Our results demonstrate that plasma 4βHC and genetic LXR variants do not play a major role in PE and BP regulation during pregnancy. However, key LXR target genes involved in lipid metabolism were expressed differently in normal and PE pregnancies. Further research is needed to understand the complexities of oxysterols, LXRs, and their potential contributions to placental function and pregnancy outcomes. Plasma 4βHC and genetic LXR variants do not play a major role in PE and BP regulation during pregnancy.Plasma 4βHC was inversely correlated with the maternal body mass index.The expression of LXR target genes APOD, TGM2, SCARB1 and LPCAT3 had significant difference between the PE and normal pregnancies. Plasma 4βHC and genetic LXR variants do not play a major role in PE and BP regulation during pregnancy. Plasma 4βHC was inversely correlated with the maternal body mass index. The expression of LXR target genes APOD, TGM2, SCARB1 and LPCAT3 had significant difference between the PE and normal pregnancies.
DOI: 10.6084/m9.figshare.28890889.v1
title: Role of oxysterol 4β-hydroxycholesterol and liver X receptor alleles in pre-eclampsia

description: Liver X receptors (LXRs) are expressed in placenta and may be associated with pre-eclampsia (PE). Oxysterols act as agonists for LXRs. We recently proposed a new blood pressure-regulating circuit with oxysterol 4β-hydroxycholesterol (4βHC) acting as a hypotensive factor <i>via</i> LXRs. This study investigated the association between maternal plasma 4βHC, blood pressure (BP) indices, placental expression of LXR target genes, and patient characteristics using data from the Finnish Genetics of Pre-Eclampsia Consortium (FINNPEC) cohort. Plasma samples of 144 women with PE and 38 healthy pregnant controls as well as 44 PE and 40 control placental samples were available. In addition, genetic data from the FinnGen project was utilized to explore the associations of LXR alleles with PE and pregnancy hypertension. There were no significant associations between 4βHC and BP or maternal and perinatal characteristics in FINNPEC cohort. However, plasma 4βHC was inversely correlated with the maternal body mass index. There were no associations with the genetic variants of LXRs with PE in FinnGen. LXR target genes APOD, SCARB1, TGM2, and LPCAT3 were expressed differently between PE and normal pregnancies in placental samples of FINNPEC. Our results demonstrate that plasma 4βHC and genetic LXR variants do not play a major role in PE and BP regulation during pregnancy. However, key LXR target genes involved in lipid metabolism were expressed differently in normal and PE pregnancies. Further research is needed to understand the complexities of oxysterols, LXRs, and their potential contributions to placental function and pregnancy outcomes. Plasma 4βHC and genetic LXR variants do not play a major role in PE and BP regulation during pregnancy.Plasma 4βHC was inversely correlated with the maternal body mass index.The expression of LXR target genes APOD, TGM2, SCARB1 and LPCAT3 had significant difference between the PE and normal pregnancies. Plasma 4βHC and genetic LXR variants do not play a major role in PE and BP regulation during pregnancy. Plasma 4βHC was inversely correlated with the maternal body mass index. The expression of LXR target genes APOD, TGM2, SCARB1 and LPCAT3 had significant difference between the PE and normal pregnancies.
DOI: 10.6084/m9.figshare.28730146
title: Elevated circulating IL-8 correlates with poor prognosis in urological cancers: a meta-analysis and bioinformatic validation

description: Interleukin-8 (IL-8) is a key cytokine that has been implicated in multiple aspects of cancer progression and therapeutic resistance. Elevated levels of circulating IL-8 (cIL-8) have been implicated in adverse clinical outcomes among patients with urological cancers. However, definitive evidence consolidating these observations remains lacking. The present study aims to synthesize the existing research findings to provide a comprehensive, evidence-based reference for clinical practice. A systematic literature search was conducted to identify relevant studies that reported on the prognostic impact of cIL-8 levels in urological cancer patients. Hazard ratios (HRs) for overall survival (OS) and progression-free survival (PFS) were extracted and pooled to estimate the overall effect. Furthermore, Kaplan–Meier’s survival analyses were conducted using RNA-seq data from The Cancer Genome Atlas (TCGA) through the Gene Expression Profiling Interactive Analysis 2 (GEPIA 2) online tool to validate the observed associations. A total of 19 cohorts encompassing 2740 patients from 12 studies were included in the meta-analysis. The findings revealed that elevated cIL-8 levels were significantly associated with inferior OS (HR: 1.86; 95% confidence intervals (CI): 1.72–2.02) and PFS (HR: 1.59; 95%CI: 1.25–2.03) in patients with urological cancers. The consistency and validity of these results were further supported by survival analyses performed using the GEPIA 2 tool. This study, which is the first meta-analysis to systematically examine the prognostic significance of cIL-8 in urological cancers, supported by bioinformatics validation, confirms that elevated cIL-8 levels serve as a potential biomarker for predicting adverse outcomes. Our findings underscore the importance of targeting IL-8 as a therapeutic strategy to overcome treatment resistance and improve outcomes for urological cancer patients. Further research into IL-8-targeted therapies and their integration into clinical practice is urgently needed to enhance the treatment landscape for urological cancers.
DOI: 10.6084/m9.figshare.28730146.v1
title: Elevated circulating IL-8 correlates with poor prognosis in urological cancers: a meta-analysis and bioinformatic validation

description: Interleukin-8 (IL-8) is a key cytokine that has been implicated in multiple aspects of cancer progression and therapeutic resistance. Elevated levels of circulating IL-8 (cIL-8) have been implicated in adverse clinical outcomes among patients with urological cancers. However, definitive evidence consolidating these observations remains lacking. The present study aims to synthesize the existing research findings to provide a comprehensive, evidence-based reference for clinical practice. A systematic literature search was conducted to identify relevant studies that reported on the prognostic impact of cIL-8 levels in urological cancer patients. Hazard ratios (HRs) for overall survival (OS) and progression-free survival (PFS) were extracted and pooled to estimate the overall effect. Furthermore, Kaplan–Meier’s survival analyses were conducted using RNA-seq data from The Cancer Genome Atlas (TCGA) through the Gene Expression Profiling Interactive Analysis 2 (GEPIA 2) online tool to validate the observed associations. A total of 19 cohorts encompassing 2740 patients from 12 studies were included in the meta-analysis. The findings revealed that elevated cIL-8 levels were significantly associated with inferior OS (HR: 1.86; 95% confidence intervals (CI): 1.72–2.02) and PFS (HR: 1.59; 95%CI: 1.25–2.03) in patients with urological cancers. The consistency and validity of these results were further supported by survival analyses performed using the GEPIA 2 tool. This study, which is the first meta-analysis to systematically examine the prognostic significance of cIL-8 in urological cancers, supported by bioinformatics validation, confirms that elevated cIL-8 levels serve as a potential biomarker for predicting adverse outcomes. Our findings underscore the importance of targeting IL-8 as a therapeutic strategy to overcome treatment resistance and improve outcomes for urological cancer patients. Further research into IL-8-targeted therapies and their integration into clinical practice is urgently needed to enhance the treatment landscape for urological cancers.
DOI: 10.15468/dl.7gmb6v
title: Occurrence Download

description: A dataset containing 0 species occurrences available in GBIF matching the query:
{"type":"and","predicates":[{"type":"within","geometry":"POLYGON ((98.985 1.99118, 98.91469499999999 1.985612, 98.84612199999999 1.969044, 98.78097200000001 1.941885, 98.720849 1.904804, 98.667233 1.858715, 98.62144600000001 1.804752, 98.584614 1.744246, 98.557644 1.678687, 98.54119799999999 1.60969, 98.535681 1.538952, 98.541228 1.468217, 98.5577 1.399226, 98.58469100000001 1.333678, 98.62153600000001 1.273185, 98.667328 1.219237, 98.720939 1.173162, 98.781049 1.136094, 98.84617799999999 1.108945, 98.91472400000001 1.092384, 98.985 1.086818, 99.05527600000001 1.092384, 99.123822 1.108945, 99.188951 1.136094, 99.249061 1.173162, 99.302672 1.219237, 99.34846400000001 1.273185, 99.38530900000001 1.333678, 99.4123 1.399226, 99.428772 1.468217, 99.434319 1.538952, 99.428802 1.60969, 99.412356 1.678687, 99.385386 1.744246, 99.34855399999999 1.804752, 99.302767 1.858715, 99.249151 1.904804, 99.18902799999999 1.941885, 99.123878 1.969044, 99.055305 1.985612, 98.985 1.99118))"},{"type":"equals","key":"CLASS_KEY","value":"212","matchCase":false},{"type":"greaterThanOrEquals","key":"YEAR","value":"2015","matchCase":false},{"type":"not","predicate":{"type":"in","key":"BASIS_OF_RECORD","values":["MATERIAL_CITATION","MATERIAL_SAMPLE","PRESERVED_SPECIMEN"],"matchCase":false}},{"type":"lessThanOrEquals","key":"COORDINATE_UNCERTAINTY_IN_METERS","value":"10000","matchCase":false},{"type":"equals","key":"LICENSE","value":"CC BY 4.0","matchCase":false}]}

 The dataset includes 0 records from 0 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0003099-260120142942310/datasets/export for details.
DOI: 10.6084/m9.figshare.29371092
title: Association between circulating irisin level and depression: a systematic review and meta-analysis

description: Previous studies have presented controversial results about the association between irisin and depression. This research is designed to explore the circulating irisin levels in depressive patients. From the earliest available records up to 18 July 2024, searches were conducted in databases of PubMed, Embase, Web of Science, the Cochrane Library, and Scopus, in order to identify the relevant articles assessing the correlation between irisin and depression in humans. Two reviewers screened reports, retrieved and collected data independently. Totally, eight articles with 2044 samples (733 depressive patients and 1311 non-depressive individuals) were involved. The results indicated lower circulating irisin levels in depression (standardized mean difference [SMD] = 0.60, 95% confidence interval [CI]: 0.08 to 1.12, <i>p</i> = 0.02). Subgroup analysis revealed decreased irisin levels in depressive Asian patients (SMD = 0.47, 95% CI: 0.05 to 0.90, <i>p</i> = 0.03), sample size greater than 100 participants (SMD = 1.20, 95% CI: 0.48 to 1.93, <i>p</i> = 0.001), ELISA kits not from Phoenix Pharmaceuticals (SMD = 0.47, 95% CI: 0.05 to 0.90, <i>p</i> = 0.03), blood sample of serum (SMD = 0.79, 95% CI: 0.18 to 1.40, <i>p</i> = 0.01), studies with two genders (SMD = 0.85, 95% CI: 0.26 to 1.43, <i>p</i> = 0.005). Moreover, six studies computed the correlation factor (r) values between irisin levels and depressive scores, and the combined findings indicated an inverse correlation for these two variables (r = −0.47, 95% CI: −0.69 to −0.24, <i>p</i> &lt; 0.001). The results of this research demonstrated that irisin levels were decreased in depressive patients, and there was a negative correlation between irisin levels and depressive scores, indicating that the lower the circulating irisin level, the more severe the depressive symptoms.
DOI: 10.6084/m9.figshare.29371092.v1
title: Association between circulating irisin level and depression: a systematic review and meta-analysis

description: Previous studies have presented controversial results about the association between irisin and depression. This research is designed to explore the circulating irisin levels in depressive patients. From the earliest available records up to 18 July 2024, searches were conducted in databases of PubMed, Embase, Web of Science, the Cochrane Library, and Scopus, in order to identify the relevant articles assessing the correlation between irisin and depression in humans. Two reviewers screened reports, retrieved and collected data independently. Totally, eight articles with 2044 samples (733 depressive patients and 1311 non-depressive individuals) were involved. The results indicated lower circulating irisin levels in depression (standardized mean difference [SMD] = 0.60, 95% confidence interval [CI]: 0.08 to 1.12, <i>p</i> = 0.02). Subgroup analysis revealed decreased irisin levels in depressive Asian patients (SMD = 0.47, 95% CI: 0.05 to 0.90, <i>p</i> = 0.03), sample size greater than 100 participants (SMD = 1.20, 95% CI: 0.48 to 1.93, <i>p</i> = 0.001), ELISA kits not from Phoenix Pharmaceuticals (SMD = 0.47, 95% CI: 0.05 to 0.90, <i>p</i> = 0.03), blood sample of serum (SMD = 0.79, 95% CI: 0.18 to 1.40, <i>p</i> = 0.01), studies with two genders (SMD = 0.85, 95% CI: 0.26 to 1.43, <i>p</i> = 0.005). Moreover, six studies computed the correlation factor (r) values between irisin levels and depressive scores, and the combined findings indicated an inverse correlation for these two variables (r = −0.47, 95% CI: −0.69 to −0.24, <i>p</i> &lt; 0.001). The results of this research demonstrated that irisin levels were decreased in depressive patients, and there was a negative correlation between irisin levels and depressive scores, indicating that the lower the circulating irisin level, the more severe the depressive symptoms.
DOI: 10.6084/m9.figshare.30563777
title: Identification and prognosis of low office and ambulatory blood pressure in patients with heart failure

description: Low blood pressure (BP) limits the up-titration of guideline-directed medical therapies (GDMTs) and predicts poor outcomes in heart failure (HF). We assessed the value of ambulatory BP monitoring (ABPM) in detecting low BP and its impact on GDMTs optimization and prognosis in HF. In 491 HF patients initiating GDMTs from the Risk Evaluation and Management in Heart Failure (REM-HF) study since April 2018 to December 2022, ABPM was measured in addition to office BP. Participants were classified as sustained low systolic BP (SBP) (24-hour and office SBP &lt; 120 mmHg), masked low SBP (24-hour SBP &lt; 120 mmHg, office SBP ≥ 120 mmHg), and no low SBP. The primary outcome was a composite of all-cause mortality and HF rehospitalization. GDMTs target dose achievement was assessed at 3 months. Logistic regression and Cox regression models were used to assess GDMTs optimization and outcomes across SBP groups. Sustained, masked, and no low SBP were observed in 25.3%, 30.8%, and 44.0% of patients, respectively. Both sustained (OR 2.36, 95%CI 1.25–4.47) and masked low SBP (OR 2.32, 95%CI 1.11–4.87) groups were associated with lower likelihood of achieving GDMTs target doses. Over a median 21-month follow-up, all-cause mortality and HF rehospitalization rates were higher in sustained (HR 2.45, 95% CI 1.56–3.86) and masked low SBP (HR 1.68, 95% CI 1.08–2.62) groups. No difference was found in the target dose achievement and outcomes between the two low SBP groups. Sustained and masked low SBP were common in HF and both associated with GDMTs intolerance and adverse outcomes.
DOI: 10.6084/m9.figshare.30563777.v1
title: Identification and prognosis of low office and ambulatory blood pressure in patients with heart failure

description: Low blood pressure (BP) limits the up-titration of guideline-directed medical therapies (GDMTs) and predicts poor outcomes in heart failure (HF). We assessed the value of ambulatory BP monitoring (ABPM) in detecting low BP and its impact on GDMTs optimization and prognosis in HF. In 491 HF patients initiating GDMTs from the Risk Evaluation and Management in Heart Failure (REM-HF) study since April 2018 to December 2022, ABPM was measured in addition to office BP. Participants were classified as sustained low systolic BP (SBP) (24-hour and office SBP &lt; 120 mmHg), masked low SBP (24-hour SBP &lt; 120 mmHg, office SBP ≥ 120 mmHg), and no low SBP. The primary outcome was a composite of all-cause mortality and HF rehospitalization. GDMTs target dose achievement was assessed at 3 months. Logistic regression and Cox regression models were used to assess GDMTs optimization and outcomes across SBP groups. Sustained, masked, and no low SBP were observed in 25.3%, 30.8%, and 44.0% of patients, respectively. Both sustained (OR 2.36, 95%CI 1.25–4.47) and masked low SBP (OR 2.32, 95%CI 1.11–4.87) groups were associated with lower likelihood of achieving GDMTs target doses. Over a median 21-month follow-up, all-cause mortality and HF rehospitalization rates were higher in sustained (HR 2.45, 95% CI 1.56–3.86) and masked low SBP (HR 1.68, 95% CI 1.08–2.62) groups. No difference was found in the target dose achievement and outcomes between the two low SBP groups. Sustained and masked low SBP were common in HF and both associated with GDMTs intolerance and adverse outcomes.
DOI: 10.6084/m9.figshare.28334797
title: Persistent lipoprotein(a) exposure and its association with clinical outcomes after acute myocardial infarction: a longitudinal cohort study

description: To assess the link between persistent lipoprotein(a) [Lp(a)] exposure levels and clinical outcomes in patients with acute myocardial infarction (AMI). This longitudinal cohort study included 1131 AMI patients, categorizing persistent Lp(a) exposure based on measurements at admission and after 1 year. Patients were segmented into four groups using a 300 mg/L Lp(a) threshold: (1) persistent low Lp(a) (low<sub>on admission</sub> – low<sub>at 1 year</sub>); (2) fortified Lp(a) (low<sub>on admission</sub> – high<sub>at 1 year</sub>); (3) attenuated Lp(a) (high<sub>on admission</sub> – low<sub>at 1 year</sub>); and (4) persistent high Lp(a) (high<sub>on admission</sub> – high<sub>at 1 year</sub>). Multivariate Cox regression, subgroup analysis and sensitivity analysis assessed the association between Lp(a) trajectories and major adverse cardiovascular and cerebrovascular events (MACCE), cardiovascular death, non-fatal MI, non-fatal stroke, unplanned revascularization, and all-cause death. Over a median 50-month follow-up, 343 (35.70%) patients encountered MACCE, and 210 (18.70%) died, including 126 (11.20%) from cardiovascular causes. The group with persistent high Lp(a) faced increased risk of MACCE (HR<sub>adjusted</sub>, 1.871; 95% CI: 1.474–2.374), non-fatal stroke (HR<sub>adjusted</sub>, 1.647; 95% CI: 1.031–2.632), unplanned revascularization (HR<sub>adjusted</sub>, 1.571; 95% CI: 1.008–2.449), and both all-cause (HR<sub>adjusted</sub>, 1.546; 95% CI: 1.134–2.108) and cardiovascular death (HR<sub>adjusted</sub>, 2.163; 95% CI: 1.405–3.331), compared to the persistent low Lp(a) group. In AMI patients, sustained high Lp(a) levels were significantly associated with increased risk of MACCE, non-fatal stroke, unplanned revascularization, and both all-cause and cardiovascular death.
DOI: 10.6084/m9.figshare.28334797.v1
title: Persistent lipoprotein(a) exposure and its association with clinical outcomes after acute myocardial infarction: a longitudinal cohort study

description: To assess the link between persistent lipoprotein(a) [Lp(a)] exposure levels and clinical outcomes in patients with acute myocardial infarction (AMI). This longitudinal cohort study included 1131 AMI patients, categorizing persistent Lp(a) exposure based on measurements at admission and after 1 year. Patients were segmented into four groups using a 300 mg/L Lp(a) threshold: (1) persistent low Lp(a) (low<sub>on admission</sub> – low<sub>at 1 year</sub>); (2) fortified Lp(a) (low<sub>on admission</sub> – high<sub>at 1 year</sub>); (3) attenuated Lp(a) (high<sub>on admission</sub> – low<sub>at 1 year</sub>); and (4) persistent high Lp(a) (high<sub>on admission</sub> – high<sub>at 1 year</sub>). Multivariate Cox regression, subgroup analysis and sensitivity analysis assessed the association between Lp(a) trajectories and major adverse cardiovascular and cerebrovascular events (MACCE), cardiovascular death, non-fatal MI, non-fatal stroke, unplanned revascularization, and all-cause death. Over a median 50-month follow-up, 343 (35.70%) patients encountered MACCE, and 210 (18.70%) died, including 126 (11.20%) from cardiovascular causes. The group with persistent high Lp(a) faced increased risk of MACCE (HR<sub>adjusted</sub>, 1.871; 95% CI: 1.474–2.374), non-fatal stroke (HR<sub>adjusted</sub>, 1.647; 95% CI: 1.031–2.632), unplanned revascularization (HR<sub>adjusted</sub>, 1.571; 95% CI: 1.008–2.449), and both all-cause (HR<sub>adjusted</sub>, 1.546; 95% CI: 1.134–2.108) and cardiovascular death (HR<sub>adjusted</sub>, 2.163; 95% CI: 1.405–3.331), compared to the persistent low Lp(a) group. In AMI patients, sustained high Lp(a) levels were significantly associated with increased risk of MACCE, non-fatal stroke, unplanned revascularization, and both all-cause and cardiovascular death.